Reprint of: Effect of pregabalin initiation on diuretic requirements in patients with chronic heart failure

IF 2.5 4区医学 Q3 PHARMACOLOGY & PHARMACY

Journal of the American Pharmacists Association Pub Date : 2024-07-01 DOI:10.1016/j.japh.2024.102159

Avital Basri, Meredith A. Sigler, Kevin C. Kelly, Dawn H. Lopez, Carlos A. Alvarez

{"title":"Reprint of: Effect of pregabalin initiation on diuretic requirements in patients with chronic heart failure","authors":"Avital Basri, Meredith A. Sigler, Kevin C. Kelly, Dawn H. Lopez, Carlos A. Alvarez","doi":"10.1016/j.japh.2024.102159","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Literature on pregabalin use in patients with heart failure is largely limited to patient case reports and cohort studies.</div></div><div><h3>Objective</h3><div>This study aimed to evaluate the effect of pregabalin initiation on diuretic requirements in patients with heart failure.</div></div><div><h3>Methods</h3><div>A retrospective analysis of patients with heart failure who were started on pregabalin between January 1, 2014, and September 1, 2021, at the Veterans Affairs North Texas Health Care System was used. The primary objective was to determine the median change in loop diuretic dose, in furosemide dose equivalents, 6 months after pregabalin initiation.</div></div><div><h3>Results</h3><div>Of 58 patients analyzed, there was no statistically significant difference in the primary outcome (<em>P</em> = 0.162). The secondary outcomes were found to be nonstatistically significant, and there was no correlation between pregabalin dose and outcomes.</div></div><div><h3>Conclusion</h3><div>This represents the largest analysis of diuretic dose requirements in patients with heart failure after initiation of pregabalin. Although there was no difference in the median change of diuretic dose prescribed, pregabalin should still be used with caution.</div></div>","PeriodicalId":50015,"journal":{"name":"Journal of the American Pharmacists Association","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the American Pharmacists Association","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1544319124001791","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Literature on pregabalin use in patients with heart failure is largely limited to patient case reports and cohort studies.

Objective

This study aimed to evaluate the effect of pregabalin initiation on diuretic requirements in patients with heart failure.

Methods

A retrospective analysis of patients with heart failure who were started on pregabalin between January 1, 2014, and September 1, 2021, at the Veterans Affairs North Texas Health Care System was used. The primary objective was to determine the median change in loop diuretic dose, in furosemide dose equivalents, 6 months after pregabalin initiation.

Results

Of 58 patients analyzed, there was no statistically significant difference in the primary outcome (P = 0.162). The secondary outcomes were found to be nonstatistically significant, and there was no correlation between pregabalin dose and outcomes.

Conclusion

This represents the largest analysis of diuretic dose requirements in patients with heart failure after initiation of pregabalin. Although there was no difference in the median change of diuretic dose prescribed, pregabalin should still be used with caution.

查看原文本刊更多论文

转载：开始使用普瑞巴林对慢性心力衰竭患者利尿剂需求的影响。

背景：有关普瑞巴林在心力衰竭患者中应用的文献主要限于患者病例报告和队列研究：有关心衰患者使用普瑞巴林的文献主要局限于患者病例报告和队列研究：本研究旨在评估心衰患者开始使用普瑞巴林对利尿剂需求的影响：方法：对2014年1月1日至2021年9月1日期间在退伍军人事务部北德克萨斯医疗保健系统开始使用普瑞巴林的心衰患者进行回顾性分析。主要目的是确定开始使用普瑞巴林 6 个月后襻利尿剂剂量（呋塞米剂量当量）的中位数变化：结果：在分析的 58 名患者中，主要结果无显著统计学差异（P = 0.162）。次要结果无统计学意义，普瑞巴林剂量与结果之间无相关性：结论：这是对心衰患者开始使用普瑞巴林后的利尿剂剂量需求进行的最大规模分析。结论：这是对心力衰竭患者开始使用普瑞巴林后所需利尿剂剂量的最大规模分析。虽然利尿剂剂量的中位数变化没有差异，但仍应谨慎使用普瑞巴林。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of the American Pharmacists Association 医学-药学

CiteScore

3.30

自引率

14.30%

发文量

336

审稿时长

46 days

期刊介绍： The Journal of the American Pharmacists Association is the official peer-reviewed journal of the American Pharmacists Association (APhA), providing information on pharmaceutical care, drug therapy, diseases and other health issues, trends in pharmacy practice and therapeutics, informed opinion, and original research. JAPhA publishes original research, reviews, experiences, and opinion articles that link science to contemporary pharmacy practice to improve patient care.